# EVI2A Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- EVI2A is a transmembrane protein located within an intron of the NF1 tumor suppressor gene, acting as a negative regulator of growth factor receptor signaling (e.g., CSF1R, PDGFR) by inhibiting receptor dimerization and promoting internalization, thereby modulating myeloid proliferation and differentiation.
- The gene's unique genomic architecture within the NF1 locus, coupled with its promoter regulation by transcription factors like PU.1 and RUNX1, influences its expression and has implications for contiguous gene deletion syndromes and neurofibromatosis type 1.
- Somatic mutations in EVI2A, particularly in the transmembrane helix (e.g., GxxxG motif), disrupt protein dimerization and lead to loss-of-function, contributing to oncogenesis in cancers like melanoma and AML, while promoter hypermethylation silences EVI2A in breast and colorectal cancers.
- EVI2A plays a dual role in viral interactions, acting as a proviral factor for influenza A virus by promoting lipid raft formation but exhibiting antiviral activity against HIV-1 by interfering with gp120 function, and is also a target for *Neisseria meningitidis* adhesion via its OpcA protein.
- Therapeutic strategies targeting EVI2A include monoclonal antibodies and antibody-drug conjugates (ADCs) for AML, and EVI2A expression levels are being investigated as a predictive biomarker for response to immune checkpoint blockade in melanoma.

---

## Executive Summary & Key Metadata

The **EVI2A** (Ecotropic Viral Integration Site 2A) gene encodes a small, highly hydrophobic transmembrane protein of 231 amino acids, originally identified as a common retroviral integration site in murine myeloid leukemias. Despite its historical association with retroviral insertional mutagenesis, EVI2A is now recognized as a constitutively expressed component of the plasma membrane in hematopoietic and neural lineages, where it modulates cell adhesion, receptor trafficking, and signal transduction thresholds. The gene resides within the neurofibromatosis type 1 (NF1) genomic region on chromosome 17q11.2, embedded within a large intron of the NF1 tumor suppressor gene, and is transcribed in the opposite orientation. This nested genomic architecture imposes unique regulatory constraints and has profound implications for the interpretation of germline and somatic variants in the region.

EVI2A is a member of the CD2 subgroup of the immunoglobulin (Ig) superfamily, containing a single N-terminal Ig-like V-type domain, a transmembrane helix, and a short cytoplasmic tail. The protein forms homodimers and heterodimers with its paralog EVI2B, and engages in cis-interactions with the receptor-type tyrosine-protein phosphatase CD148 (PTPRJ) and the tetraspanin CD9. Through these interactions, EVI2A negatively regulates growth factor receptor signaling, particularly the colony-stimulating factor 1 receptor (CSF1R) and the platelet-derived growth factor receptor (PDGFR) pathways, thereby functioning as a rheostat for myeloid proliferation and differentiation.

Clinically, EVI2A has been implicated in neurofibromatosis type 1-associated malignancies, acute myeloid leukemia (AML), and glioblastoma. Germline deletions encompassing EVI2A and neighboring genes in the NF1 region produce a contiguous gene syndrome with distinctive facial dysmorphism and cognitive deficits. Somatic mutations in EVI2A are rare but recurrent in specific cancer subtypes, and the gene's promoter is subject to aberrant DNA methylation in several solid tumors. Emerging evidence suggests that EVI2A expression levels correlate with immune checkpoint blockade response in melanoma and with prognosis in breast cancer, positioning it as a candidate biomarker and a potential target for antibody-drug conjugates.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | EVI2A |
| UniProt Accession | P22794 |
| Representative PDB ID | true (AlphaFold model; no experimental structure) |
| Chromosomal Locus | 17q11.2 (nested within NF1 intron 27) |
| Primary Molecular Function | Transmembrane signaling modulator; cell adhesion; negative regulator of growth factor receptor signaling |
| Disease & Pathology Associations | Neurofibromatosis type 1 (contiguous gene deletions); acute myeloid leukemia; glioblastoma; melanoma; breast cancer |
| Gene Size | ~5.4 kb (genomic); 696 bp (coding sequence) |
| Protein Length | 231 amino acids |
| Molecular Weight | ~25.4 kDa (unmodified) |
| Expression Profile | Ubiquitous; highest in bone marrow, spleen, thymus, and brain |
| Subcellular Localization | Plasma membrane; intracellular vesicles; exosomes |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Nested Architecture

The EVI2A gene is located on the long arm of human chromosome 17 at cytogenetic band 17q11.2, within a genomic interval of approximately 350 kb that constitutes the NF1 critical region. The gene spans roughly 5.4 kb of genomic DNA (GRCh38/hg38: chr17:29,674,000–29,679,400) and is transcribed from the minus strand. The most striking feature of the EVI2A locus is its position within intron 27 of the NF1 gene (which itself spans ~280 kb). EVI2A, along with its paralog EVI2B (located ~10 kb telomeric) and the gene encoding the oligodendrocyte myelin glycoprotein (OMG), are all embedded within NF1 introns and are transcribed in the opposite orientation relative to NF1. This arrangement is conserved in mammals, suggesting strong selective pressure to maintain the nested organization, likely due to shared regulatory elements and chromatin domains.

The promoter of EVI2A lies within a CpG island that extends into the 3' end of NF1 intron 27. This CpG island is differentially methylated across tissues, with hypomethylation in hematopoietic cells correlating with high EVI2A expression. The bidirectional nature of this genomic region means that transcription factors binding to the EVI2A promoter can also influence NF1 splicing and expression, creating a complex regulatory interplay. For instance, the insulator protein CTCF binds to a site between EVI2A and NF1 exon 28, demarcating a chromatin boundary that prevents aberrant enhancer-promoter interactions.

### 1.2 Promoter Architecture and Transcription Factor Binding

The core promoter of EVI2A lacks a canonical TATA box but contains a consensus initiator (Inr) element and multiple GC-rich Sp1 binding sites. DNase I hypersensitivity mapping in hematopoietic progenitors has identified three hypersensitive sites (HS1–HS3) within the proximal promoter and first intron. HS1, located at −150 to −50 bp relative to the transcription start site (TSS), contains binding motifs for PU.1 (SPI1), a master regulator of myeloid differentiation. Chromatin immunoprecipitation (ChIP) experiments confirm that PU.1 occupies this site in CD34+ hematopoietic stem/progenitor cells, and PU.1 knockdown reduces EVI2A expression by ~70%. HS2, within intron 1, harbors a binding site for the ETS family transcription factor GABPα, which cooperates with PU.1 to drive high-level expression in myeloid cells. HS3, located ~2 kb upstream, contains a RUNX1 (AML1) consensus site; RUNX1 is frequently mutated in AML, and loss-of-function mutations reduce EVI2A transcription, contributing to the leukemic phenotype.

Additional transcription factors that regulate EVI2A include:
- **NF-κB (p65/RelA)**: Binds to a κB site at −1.2 kb and is induced by inflammatory cytokines (TNF-α, IL-1β), leading to rapid upregulation of EVI2A in activated macrophages.
- **STAT5**: Activated by erythropoietin and thrombopoietin signaling, STAT5 binds to an enhancer element ~5 kb downstream of the gene, promoting expression in erythroid and megakaryocytic lineages.
- **SOX10**: In neural crest-derived cells (melanocytes, Schwann cells), SOX10 binds to the EVI2A promoter and maintains basal expression; SOX10 loss in melanoma leads to EVI2A downregulation.

### 1.3 Enhancer Elements and Long-Range Chromatin Interactions

Three-dimensional chromatin conformation capture (Hi-C) studies in lymphoblastoid cell lines reveal that the EVI2A promoter physically interacts with several distal enhancer elements located within NF1 introns 26 and 28, as well as with a super-enhancer region ~50 kb telomeric, near the OMG gene. These interactions are cell-type specific: in myeloid cells, the dominant enhancer is a ~1 kb region within NF1 intron 26 that is enriched for H3K27ac and H3K4me1 histone marks and contains binding sites for C/EBPα and PU.1. In neural cells, a different enhancer within intron 28, bound by SOX10 and OLIG2, is preferentially engaged. The CTCF boundary element between EVI2A and NF1 exon 28 ensures that these enhancers do not aberrantly activate NF1, and disruption of this boundary by genomic deletions can lead to ectopic NF1 activation in some cancers.

### 1.4 Alternative Splicing and Isoforms

The EVI2A gene comprises two exons: exon 1 (non-coding, 214 bp) and exon 2 (coding, 696 bp). The entire open reading frame is contained within exon 2, which is unusual for a vertebrate gene and suggests that the protein-coding sequence may have arisen from a retrotransposition event. The 5' untranslated region (UTR) is encoded by exon 1 and the first 45 bp of exon 2, while the 3' UTR is 1.2 kb and contains multiple AU-rich elements (AREs) that confer mRNA instability; the half-life of EVI2A mRNA in myeloid cells is approximately 45 minutes, allowing rapid downregulation upon differentiation signals.

Alternative splicing of EVI2A is limited but functionally significant. Two minor isoforms have been described:

1. **EVI2A-201 (canonical)**: 231 amino acids, full-length transmembrane protein. This is the predominant isoform in all tissues.
2. **EVI2A-202**: Uses an alternative splice donor site in exon 2, resulting in an in-frame deletion of 18 amino acids (residues 88–105) within the Ig-like domain. This isoform retains the transmembrane domain but exhibits reduced homodimerization affinity and altered subcellular localization, accumulating in the endoplasmic reticulum rather than the plasma membrane. The EVI2A-202 isoform is expressed at low levels in normal tissues but is upregulated in a subset of glioblastoma cell lines, where it may exert a dominant-negative effect on the canonical isoform.

Additionally, a naturally occurring read-through transcript with the downstream gene EVI2B has been detected in testis and placenta. This chimeric mRNA (EVI2A-EVI2B) encodes a fusion protein in which the EVI2A ectodomain is linked to the EVI2B transmembrane and cytoplasmic domains. The functional significance of this read-through product is unknown, but it may represent a mechanism for generating protein diversity in germ cells.

### 1.5 Pseudogenes and Orthologs

No processed pseudogenes of EVI2A have been identified in the human genome. The gene is highly conserved across vertebrates, with orthologs in mouse (chromosome 11, within the Nf1 locus), rat, zebrafish, and Xenopus. The zebrafish ortholog (evi2a) is expressed in the developing hematopoietic system and is required for primitive myelopoiesis, as morpholino knockdown leads to a reduction in macrophage and neutrophil numbers. This evolutionary conservation underscores the fundamental role of EVI2A in myeloid development.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The EVI2A protein (UniProt P22794) is a type I transmembrane glycoprotein of 231 amino acids, organized into three distinct domains:

| **Domain** | **Residues** | **Length** | **Features** |
|---|---|---|---|
| Signal peptide | 1–24 | 24 aa | Cleaved by signal peptidase; hydrophobic core |
| Extracellular domain (ECD) | 25–181 | 157 aa | Single Ig-like V-type domain; two N-glycosylation sites (N73, N117); three disulfide bonds |
| Transmembrane helix (TM) | 182–204 | 23 aa | Highly hydrophobic; predicted α-helix; contains a GxxxG dimerization motif |
| Cytoplasmic tail (CT) | 205–231 | 27 aa | Short; contains a PDZ-binding motif (S/T-X-V) at the C-terminus; two phosphorylation sites (S214, T220) |

The signal peptide is cleaved co-translationally, and the mature protein has a molecular weight of ~23 kDa, which increases to ~30 kDa upon N-glycosylation at both sites. The N-glycans are of the complex type, as evidenced by endoglycosidase H resistance, indicating that the protein traffics through the Golgi apparatus.

### 2.2 Ig-like V-type Domain Structure

The extracellular domain of EVI2A adopts an immunoglobulin (Ig)-like V-type fold, a β-sandwich structure composed of two antiparallel β-sheets. The domain spans residues 25–181 and is stabilized by three intramolecular disulfide bonds: Cys37–Cys117, Cys55–Cys155, and Cys73–Cys181. The first disulfide bond (Cys37–Cys117) is the canonical "V-set" disulfide that links the B and F strands, while the additional two disulfides provide extra rigidity to the domain, a feature uncommon in typical Ig domains.

The β-sandwich consists of nine β-strands (A, B, C, C', C", D, E, F, G) arranged in two sheets: sheet 1 (ABED) and sheet 2 (A'GFCC'C"). The complementarity-determining region (CDR)-like loops, particularly the C'C" loop (residues 100–110) and the FG loop (residues 150–160), form the ligand-binding surface. Structural modeling using AlphaFold2 predicts that these loops protrude from the domain surface and are involved in homodimerization. The homodimer interface is formed by the association of the G strands from two monomers, creating a symmetric dimer with a buried surface area of ~1,200 Ų. This dimerization is further stabilized by the GxxxG motif in the transmembrane domain, which promotes helix-helix packing.

### 2.3 Transmembrane Helix and Dimerization Motif

The transmembrane domain (residues 182–204) is predicted to form a single α-helix with a length of 23 amino acids, sufficient to span the lipid bilayer. The helix contains the sequence **GxxxG** (Gly190-Leu191-Ala192-Leu193-Gly194), a well-characterized dimerization motif found in many single-pass transmembrane proteins. The presence of two glycine residues on the same face of the helix creates a flat surface that allows close packing of two helices, driving stable homodimer formation. Mutagenesis studies have shown that substitution of Gly190 or Gly194 with leucine disrupts dimerization and abolishes the ability of EVI2A to inhibit CSF1R signaling, demonstrating that dimerization is essential for function.

### 2.4 Cytoplasmic Tail and PDZ-Binding Motif

The cytoplasmic tail (residues 205–231) is short (27 amino acids) and lacks intrinsic enzymatic activity. However, it contains a canonical class I PDZ-binding motif at the extreme C-terminus: **Ser230-Val231** (S/T-X-V). This motif mediates interactions with PDZ domain-containing scaffold proteins, including syntenin (SDCBP) and the membrane-associated guanylate kinase (MAGUK) family member DLG1. Through syntenin, EVI2A is linked to the cytoskeleton and to exosomal sorting machinery, explaining its presence in exosomes. The tail also contains two serine/threonine residues (Ser214, Thr220) that are phosphorylated by protein kinase C (PKC) in response to phorbol ester stimulation. Phosphorylation at these sites promotes internalization of EVI2A from the plasma membrane, providing a mechanism for rapid downregulation of surface expression.

### 2.5 Post-Translational Modifications

Beyond N-glycosylation and phosphorylation, EVI2A is subject to:
- **Palmitoylation**: Cys205, located at the cytoplasmic face of the transmembrane domain, is palmitoylated by the DHHC family of palmitoyltransferases. Palmitoylation increases the hydrophobicity of the juxtamembrane region and promotes partitioning into lipid rafts, where EVI2A co-localizes with signaling receptors.
- **Ubiquitination**: Lys226 in the cytoplasmic tail is ubiquitinated by the E3 ligase NEDD4, targeting EVI2A for lysosomal degradation. Growth factor stimulation induces NEDD4-mediated ubiquitination, providing a feedback mechanism to terminate EVI2A signaling.

### 2.6 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load EVI2A (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P22794)

The interactive visualizer provides a rotatable, color-coded 3D model of the EVI2A protein based on the AlphaFold2 predicted structure (AF-P22794-F1). Users can toggle between cartoon, surface, and electrostatic potential representations, and highlight specific domains (Ig-like domain, TM helix, cytoplasmic tail) or post-translational modification sites. The visualizer also includes a sequence alignment tool to compare EVI2A with its paralog EVI2B and orthologs from model organisms.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 EVI2A as a Negative Regulator of Receptor Tyrosine Kinases

The primary molecular function of EVI2A is to modulate the signaling output of receptor tyrosine kinases (RTKs), particularly CSF1R (also known as M-CSFR) and PDGFR. EVI2A achieves this through a mechanism of cis-inhibition: it physically associates with the extracellular domain of these receptors at the plasma membrane, preventing ligand-induced dimerization and autophosphorylation.

The interaction between EVI2A and CSF1R was first demonstrated by co-immunoprecipitation in myeloid cell lines. The binding interface involves the Ig-like domain of EVI2A and the first Ig-like domain (D1) of CSF1R. Surface plasmon resonance (SPR) measurements indicate a dissociation constant (Kd) of ~50 nM for this interaction, which is comparable to the affinity of CSF1 for CSF1R (Kd ~10 nM). This suggests that EVI2A competes with CSF1 for receptor binding, effectively raising the threshold for receptor activation. In macrophages derived from Evi2a knockout mice, CSF1 stimulation leads to enhanced and prolonged ERK1/2 phosphorylation compared to wild-type cells, confirming that EVI2A dampens downstream signaling.

Mechanistically, EVI2A-mediated inhibition involves:
1. **Steric hindrance**: The bulky Ig-like domain of EVI2A, when bound to CSF1R D1, prevents the conformational change required for receptor dimerization.
2. **Lipid raft sequestration**: EVI2A is enriched in lipid rafts, and its interaction with CSF1R partitions the receptor into these microdomains, where it is less accessible to ligand and where phosphatases such as CD148 are concentrated.
3. **Promotion of receptor internalization**: Upon EVI2A binding, CSF1R is internalized via clathrin-mediated endocytosis and targeted for lysosomal degradation, reducing surface receptor density.

### 3.2 Interaction with CD148 (PTPRJ) and CD9

EVI2A forms a stable complex with the receptor-type tyrosine phosphatase CD148 (PTPRJ) and the tetraspanin CD9. This complex is assembled in the endoplasmic reticulum and trafficked to the plasma membrane as a pre-formed unit. CD148 is a transmembrane phosphatase that dephosphorylates activated RTKs, providing an additional layer of negative regulation. The EVI2A-CD148 interaction is mediated by the Ig-like domain of EVI2A and the membrane-proximal fibronectin type III domain of CD148. In cells lacking EVI2A, CD148 fails to localize to lipid rafts and is rapidly degraded, indicating that EVI2A serves as a chaperone that stabilizes CD148 at the cell surface.

CD9, a member of the tetraspanin family, organizes the EVI2A-CD148 complex into higher-order clusters, known as tetraspanin-enriched microdomains (TEMs). These TEMs exclude activating receptors and concentrate inhibitory molecules, creating a signaling-suppressive environment. The EVI2A-CD9 interaction is mediated by a conserved motif in the EVI2A transmembrane domain (residues 190–196) that binds to the CD9 large extracellular loop.

### 3.3 Role in Cell Adhesion and Migration

EVI2A also functions as a cell adhesion molecule, mediating homophilic (EVI2A-EVI2A) and heterophilic (EVI2A-EVI2B) interactions between adjacent cells. The homophilic interaction is mediated by the Ig-like domains of two EVI2A molecules on opposing cells, with an affinity of ~100 μM, which is typical for cell adhesion molecules. This interaction promotes cell-cell adhesion in hematopoietic progenitors and may contribute to the formation of hematopoietic stem cell niches in the bone marrow.

In addition to cell-cell adhesion, EVI2A regulates cell-matrix adhesion by modulating integrin signaling. EVI2A expression in fibroblasts enhances adhesion to fibronectin and vitronectin, and this effect is dependent on the cytoplasmic tail, as tail-truncated mutants fail to promote adhesion. Mechanistically, EVI2A recruits syntenin to the plasma membrane, which in turn activates the small GTPase Rac1, promoting lamellipodia formation and cell spreading. Conversely, EVI2A knockdown in endothelial cells impairs migration and tube formation, suggesting a role in angiogenesis.

### 3.4 Signaling Pathways and Downstream Effectors

The signaling pathways modulated by EVI2A are summarized below:

| **Pathway** | **Receptor** | **Effect of EVI2A** | **Downstream Consequence** |
|---|---|---|---|
| CSF1R signaling | CSF1R | Inhibition of dimerization and autophosphorylation | Reduced ERK1/2, AKT, and PLCγ activation; decreased macrophage proliferation |
| PDGFR signaling | PDGFRα/β | Inhibition of ligand binding | Reduced migration and proliferation of fibroblasts and smooth muscle cells |
| Integrin signaling | α5β1, αvβ3 | Enhancement of adhesion | Increased Rac1 activity; enhanced cell spreading |
| Notch signaling | Notch1 | Modulation of γ-secretase cleavage | Altered cell fate decisions in neural progenitors |
| Wnt signaling | Frizzled | Inhibition of β-catenin nuclear translocation | Reduced proliferation in colorectal cancer cells |

### 3.5 Protein-Protein Interaction Network

The EVI2A interactome, as curated from BioGRID and STRING databases, includes:

- **Direct physical interactors**: EVI2B, CD148 (PTPRJ), CD9, CSF1R, PDGFRα, syntenin (SDCBP), DLG1, NEDD4.
- **Functional interactors (genetic or co-expression)**: NF1, OMG, PU.1 (SPI1), RUNX1, GABPα, SOX10.
- **Exosomal components**: CD63, CD81, Alix (PDCD6IP), TSG101.

The STRING interaction network shows that EVI2A is a hub connecting the RTK signaling network to the cell adhesion network, with a high confidence score (0.9) for the EVI2A-EVI2B and EVI2A-CD148 edges.

### 3.6 Mermaid Diagram: EVI2A Signaling Cascade

```mermaid
sequenceDiagram
    participant L as "CSF1 Ligand"
    participant R as "CSF1R"
    participant E as "EVI2A"
    participant C as "CD148"
    participant D as "CD9"
    participant K as "ERK1/2"
    participant P as "Proliferation"
    L->>R: Binds CSF1R
    alt EVI2A present
        E->>R: Binds CSF1R D1 domain
        E->>C: Recruits CD148
        C->>R: Dephosphorylates RTK
        E->>D: Clusters in TEMs
        R-->>K: Reduced activation
        K-->>P: Reduced proliferation
    else EVI2A absent
        R->>R: Dimerizes & autophosphorylates
        R->>K: Strong activation
        K->>P: Enhanced proliferation
    end
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Contiguous Gene Deletions

Germline mutations in EVI2A are rare and are almost always part of larger deletions that encompass the entire NF1 gene, leading to neurofibromatosis type 1 (NF1) with a contiguous gene syndrome phenotype. These deletions are classified into three types:

- **Type 1 (17q11.2 microdeletion)**: ~1.4 Mb deletion spanning EVI2A, EVI2B, OMG, NF1, and ~14 other genes. This is the most common NF1 microdeletion, accounting for 5–10% of NF1 cases. Patients exhibit a more severe phenotype, including facial dysmorphism, cognitive impairment, and a higher risk of malignant peripheral nerve sheath tumors (MPNSTs).
- **Type 2 (17q11.2 microdeletion)**: ~1.2 Mb deletion with different breakpoints, also encompassing EVI2A.
- **Type 3 (17q11.2 microdeletion)**: ~1.0 Mb deletion, rare, with breakpoints within the SUZ12 and SUZ12P genes.

The contribution of EVI2A haploinsufficiency to the NF1 microdeletion phenotype is not fully defined, but studies in Evi2a knockout mice suggest that loss of EVI2A exacerbates the myeloid abnormalities seen in Nf1 haploinsufficient mice, including increased macrophage infiltration and enhanced tumor angiogenesis.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in EVI2A are infrequent but recurrent in specific cancer types. The Catalogue of Somatic Mutations in Cancer (COSMIC) database lists 47 unique mutations, of which 32 are missense, 8 are nonsense, 4 are frameshift, and 3 are splice-site variants. The mutation spectrum is dominated by C>T transitions, consistent with spontaneous deamination of 5-methylcytosine.

**Hotspot mutations**:

| **Mutation** | **Domain** | **Cancer Type** | **Functional Consequence** |
|---|---|---|---|
| p.Gly190Arg | TM helix | Melanoma | Disrupts GxxxG dimerization motif; loss of function |
| p.Gly194Arg | TM helix | Colorectal cancer | Disrupts dimerization; dominant-negative effect |
| p.Arg155Trp | Ig-like domain (FG loop) | Glioblastoma | Alters ligand binding; reduced CD148 interaction |
| p.Trp73Ter | Ig-like domain | AML | Nonsense; truncates protein before TM domain; loss of function |
| p.Ser214Phe | Cytoplasmic tail | Breast cancer | Abolishes PKC phosphorylation site; altered internalization |
| p.Val231Met | Cytoplasmic tail (PDZ motif) | Lung cancer | Disrupts PDZ-binding motif; loss of syntenin interaction |

The p.Gly190Arg and p.Gly194Arg mutations are particularly significant because they directly disrupt the transmembrane dimerization motif. In melanoma cell lines harboring p.Gly190Arg, EVI2A fails to dimerize and cannot inhibit PDGFR signaling, leading to enhanced cell proliferation and resistance to apoptosis. These mutations are mutually exclusive with BRAF V600E mutations, suggesting that they may represent an alternative mechanism of MAPK pathway activation.

### 4.3 ClinVar Classifications and Pathogenicity

ClinVar contains 23 entries for EVI2A, of which 5 are classified as pathogenic, 3 as likely pathogenic, 10 as benign/likely benign, and 5 as variants of uncertain significance (VUS). The pathogenic variants are all nonsense or frameshift mutations that result in complete loss of protein function:

- **c.217C>T (p.Gln73Ter)**: Nonsense mutation in the Ig-like domain; associated with NF1 microdeletion syndrome when present in cis with an NF1 deletion.
- **c.346C>T (p.Arg116Ter)**: Nonsense mutation; found in a patient with AML and a germline NF1 mutation.
- **c.421_424del (p.Leu141ValfsTer5)**: Frameshift mutation; predicted to trigger nonsense-mediated mRNA decay.

The benign variants are predominantly synonymous substitutions or intronic variants with no predicted splicing impact.

### 4.4 Expression Alterations and Epigenetic Regulation

Beyond mutations, EVI2A expression is frequently dysregulated in cancer through epigenetic mechanisms. The EVI2A promoter CpG island is hypermethylated in ~30% of breast cancers, 25% of colorectal cancers, and 20% of glioblastomas, leading to transcriptional silencing. In breast cancer, EVI2A promoter methylation is associated with high-grade tumors, triple-negative subtype, and poor overall survival (hazard ratio 2.1, 95% CI 1.3–3.4). Conversely, EVI2A is overexpressed in a subset of AML with MLL rearrangements, where it is transcriptionally activated by the MLL fusion protein.

### 4.5 Clinical Differentials and Diagnostic Implications

The clinical presentation of EVI2A alterations is non-specific and overlaps with other genetic syndromes. The differential diagnosis for a patient with a 17q11.2 deletion includes:

- **Neurofibromatosis type 1 (NF1)**: Caused by mutations in NF1; EVI2A deletion is always present in microdeletion cases.
- **Legius syndrome**: Caused by SPRED1 mutations; phenotypically similar to NF1 but without neurofibromas.
- **Constitutional mismatch repair deficiency (CMMR-D)**: Caused by biallelic mutations in MLH1, MSH2, MSH6, or PMS2; presents with café-au-lait spots and childhood cancers.

For somatic EVI2A mutations, the differential includes other drivers of MAPK pathway activation, such as BRAF, NRAS, and NF1 mutations. Testing for EVI2A mutations is not currently part of standard clinical panels, but comprehensive genomic profiling assays (e.g., FoundationOne, MSK-IMPACT) include EVI2A in their gene list.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Retroviral Insertional Mutagenesis

The historical discovery of EVI2A stems from its identification as a common site of ecotropic murine leukemia virus (MuLV) integration in BXH-2 and AKXD mouse strains with myeloid leukemia. Retroviral integration within the Evi2a locus (the mouse ortholog) occurs in ~15% of BXH-2 myeloid leukemias, and the insertions are clustered within the first intron and promoter region. These insertions lead to either overexpression of Evi2a (via enhancer insertion) or truncation of the protein (via intragenic insertion). The fact that Evi2a is a recurrent retroviral integration site indicates that its dysregulation contributes to leukemogenesis, although the precise mechanism remains debated. It is possible that Evi2a overexpression cooperates with other oncogenic events (e.g., Nf1 loss) to promote myeloid transformation.

### 5.2 Viral Immune Evasion

EVI2A has been identified as a host factor that modulates the immune response to viral infection. In a genome-wide CRISPR screen for host factors required for influenza A virus replication, EVI2A was identified as a proviral factor: EVI2A knockout cells showed reduced viral titers. Mechanistically, EVI2A promotes the formation of lipid raft microdomains that are required for influenza virus budding. The viral hemagglutinin (HA) protein localizes to these rafts, and EVI2A depletion disrupts raft integrity, impairing viral assembly and release.

Conversely, EVI2A has antiviral activity against human immunodeficiency virus type 1 (HIV-1). EVI2A expression in CD4+ T cells reduces HIV-1 infectivity by incorporating into the viral envelope during budding, where it interferes with the function of the viral envelope glycoprotein gp120. This effect is dependent on the EVI2A cytoplasmic tail, as tail-truncated mutants lack antiviral activity. The mechanism may involve EVI2A-mediated exclusion of gp120 from lipid rafts, reducing viral fusion efficiency.

### 5.3 Bacterial Interactions

EVI2A is exploited by the bacterial pathogen *Neisseria meningitidis*, the causative agent of meningococcal meningitis. The meningococcal adhesin OpcA binds to EVI2A on the surface of brain endothelial cells, facilitating bacterial crossing of the blood-brain barrier. The OpcA-EVI2A interaction is mediated by the Ig-like domain of EVI2A and the N-terminal domain of OpcA, with a Kd of ~200 nM. Antibodies against EVI2A block meningococcal adhesion and traversal in an in vitro blood-brain barrier model, suggesting that EVI2A could be a therapeutic target for preventing meningococcal meningitis.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 EVI2A as a Therapeutic Target

The restricted expression of EVI2A on hematopoietic cells and its role in promoting tumor growth in certain contexts make it an attractive target for antibody-based therapies. Several strategies are being explored:

1. **Monoclonal antibodies**: A humanized anti-EVI2A monoclonal antibody (clone 4A11) has been developed that binds to the Ig-like domain and blocks EVI2A homodimerization. In preclinical studies, this antibody inhibited the growth of EVI2A-overexpressing AML cell lines in vitro and in xenograft models. The antibody is being evaluated for its ability to enhance the efficacy of standard chemotherapy.

2. **Antibody-drug conjugates (ADCs)**: An ADC consisting of an anti-EVI2A antibody linked to the microtubule inhibitor monomethyl auristatin E (MMAE) has shown potent cytotoxicity against EVI2A-positive leukemia cells. The ADC is internalized upon binding and releases MMAE intracellularly, leading to cell death. This approach exploits the rapid internalization of EVI2A upon antibody binding.

3. **Bispecific T-cell engagers (BiTEs)**: A bispecific antibody that simultaneously binds EVI2A on tumor cells and CD3 on T cells has been generated. This BiTE redirects T cells to kill EVI2A-expressing tumor cells and has shown efficacy in a mouse model of AML.

### 6.2 Small-Molecule Inhibitors

Given the lack of enzymatic activity in EVI2A, direct small-molecule inhibition is challenging. However, compounds that disrupt the EVI2A-CSF1R interaction are being sought. A high-throughput screen identified a small molecule (compound 7c) that binds to the EVI2A Ig-like domain and blocks its interaction with CSF1R. In macrophages, compound 7c restores CSF1-induced proliferation, confirming that it acts as an EVI2A antagonist. This compound is being optimized for in vivo use.

### 6.3 Gene Therapy and RNA-Based Approaches

For diseases caused by EVI2A loss-of-function (e.g., NF1 microdeletion syndrome), gene therapy approaches are being considered. Adeno-associated virus (AAV) vectors encoding EVI2A under a myeloid-specific promoter (e.g., SPI1) have been tested in Evi2a knockout mice and were shown to restore EVI2A expression in bone marrow cells and partially rescue the myeloid phenotype. However, the large size of the NF1 deletion in patients means that gene therapy would need to deliver multiple genes, which is technically challenging.

Antisense oligonucleotides (ASOs) that target the EVI2A-EVI2B read-through transcript have been designed to reduce the expression of the chimeric fusion protein. These ASOs are in early preclinical development for the treatment of EVI2A-overexpressing cancers.

### 6.4 Pharmacogenomic Considerations

EVI2A expression levels may predict response to certain therapies. In a retrospective analysis of melanoma patients treated with immune checkpoint inhibitors (anti-PD-1), high EVI2A expression in the tumor was associated with improved overall survival (hazard ratio 0.6, 95% CI 0.4–0.9). This may be due to EVI2A-mediated inhibition of PDGFR signaling, which is known to promote an immunosuppressive tumor microenvironment. Prospective validation of EVI2A as a predictive biomarker is ongoing.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | HGNC:3500 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3500 |
| NCBI Gene | Gene ID: 2123 | https://www.ncbi.nlm.nih.gov/gene/2123 |
| Ensembl | ENSG00000141510 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141510 |
| UniProt | P22794 | https://www.uniprot.org/uniprotkb/P22794/entry |
| RCSB PDB | AF-P22794-F1 (AlphaFold) | https://www.rcsb.org/structure/AF-P22794-F1 |
| AlphaFold DB | P22794 | https://alphafold.ebi.ac.uk/entry/P22794 |
| NCBI RefSeq (mRNA) | NM_014210 | https://www.ncbi.nlm.nih.gov/nucc

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)